Press release - 21/06/2022 Another step towards synthetic cells Scientists from the 2. Physics Institute at the University of Stuttgart and the Max Planck Institute for Medical Research were now able to take the next step towards synthetic cells: They introduced functional DNA-based cytoskeletons into cell-sized compartments and showed functionality. The results were recently published in Nature Chemistry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/another-step-towards-synthetic-cells
Press release - 05/03/2024 New Center for Synthetic Genomics Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU). https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-center-synthetic-genomics
Press release - 19/05/2025 How the Epstein-Barr virus promotes its spread in the body Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-epstein-barr-virus-promotes-its-spread-body
Article - 30/01/2019 candidum – computer-assisted enzyme design Industry has been using enzymes for over a hundred years. While it initially had to content itself with natural enzymes, it is now increasingly possible to design tailor-made biocatalysts with specific properties. The start-up company candidum GmbH from Stuttgart promises to achieve this faster than ever before - mostly thanks to accelerated virtual screening.https://www.gesundheitsindustrie-bw.de/en/article/news/candidum-computer-assisted-enzyme-design
Digitalisation - 04/08/2021 Eye check for all - quick and easy thanks to artificial intelligence Many eye diseases are already easily treatable, if they are detected in time. But waiting months for an ophthalmologist’s appointment seems to be the norm - that is, if you can get to see a specialist at all. The Tübingen-based start-up eye2you wants to improve this situation: it has developed a mobile retinal examination device involving a smartphone and AI. It can be used by family doctors, diabetologists and nursing staff and thus help to…https://www.gesundheitsindustrie-bw.de/en/article/news/eye-check-all-quick-and-easy-thanks-artificial-intelligence
Hearing loss - 29/06/2022 Innovative micro loudspeaker brings back hearing Hearing loss often severely restricts the lives of those affected and can only be partially reversed with conventional hearing aids. The innovative hearing aid developed by Vibrosonic GmbH from Mannheim transmits sound vibrations directly to the eardrum and can thus almost completely restore the natural hearing experience.https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-micro-loudspeaker-brings-back-hearing
Press release - 11/01/2023 Newly discovered surface structures may affect immune function Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
Press release - 20/06/2023 Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuberculosis-therapy-smallest-particles-will-deliver-drug-lungs-future
Press release - 09/04/2026 “Positions, please!” For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that (BET) proteins help activate, so blocking BET proteins should slow tumor growth. In the lab, it often did. In patients, results were mostly disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond at all.https://www.gesundheitsindustrie-bw.de/en/article/press-release/positions-please
Stem cell research - 14/03/2024 Using organoids to gain a better clinical understanding of pancreatic cancer Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer
Press release - 26/11/2024 Collaborative research centres on kidney and brain prolonged On 25 November, the German Research Foundation (DFG) announced the continued funding of two existing Collaborative Research Centres (CRC) at the University of Freiburg’s Faculty of Medicine. In CRC 1453 Nephrogenetics (NephGen), doctors and researchers are using genetic information to search for mechanisms underlying kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collaborative-research-centres-kidney-and-brain-prolonged
Dossier - 16/06/2014 Biotechnology as a tool for the production of food Biotechnology opens up numerous opportunities for the food industry. The targeted use of biotechnological methods can help reduce the quantity and number of unhealthy ingredients in foods as well as degrade allergenic substances. Genomic research and targeted breeding also greatly facilitate progress in agriculture. Food biotechnology therefore contributes significantly to saving resources, optimising harvest yields and producing better foods.https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-as-a-tool-for-the-production-of-food
Epifadin from the nasal microbiome - 28/03/2024 From the nose: novel antibiotic substance discovered Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.https://www.gesundheitsindustrie-bw.de/en/article/news/nose-novel-antibiotic-substance-discovered
Press release - 22/03/2024 New Emmy Noether junior research group for biological data science An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-biological-data-science
Gender-specific differences - 18/06/2024 Gender medicine: Why is good healthcare not a matter of course for everyone? Gender medicine is the study of gender-specific health differences. Many diseases manifest themselves differently in men and women and therapies do not always have the same effect depending on the sex of the patient being treated. There is currently not enough data on these differences. Research teams including the one led by Professor Dr. Dr. Sonja Loges from the University Medical Centre Mannheim and the DKFZ are seeking to change this.https://www.gesundheitsindustrie-bw.de/en/article/news/gender-medicine-why-good-healthcare-not-matter-course-everyone
Press release - 20/10/2022 Cytoskeleton acts as cells’ bouncer for bacteria Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
Press release - 13/12/2024 Schizophrenia: NMI observes processes in nerve cells Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/schizophrenia-nmi-observes-processes-nerve-cells
The Baden-Württemberg healthcare industry The pharmaceutical industry Baden-Württemberg is the leading location for the pharmaceutical industry in Germany. In addition to international industry giants such as Roche, Pfizer and Boehringer Ingelheim, numerous medium-sized pharmaceutical companies and innovative biotechnology companies specialising in pharmaceutical research and development are also based in this region.https://www.gesundheitsindustrie-bw.de/en/location/pharma
Press release - 07/04/2026 The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning. https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-research-booster-evolves-simplaix-collaboration-starts-next-phase
Press release - 07/04/2026 The molecular research “booster” evolves: SIMPLAIX collaboration starts the next phase Computer simulations and Artificial Intelligence are the main pillars of the “SIMPLAIX” collaboration, initiated by the Heidelberg Institute for Theoretical Studies (HITS). Together with colleagues from Heidelberg University and Karlsruhe Institute of Technology, HITS researchers are addressing challenges in the simulation of biomolecules and molecular materials by pooling their expertise in multiscale computer simulation and machine learning. https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-research-booster-evolves-simplaix-collaboration-starts-next-phase
Press release - 22/04/2026 Turning four into two: How duplicated genomes become diploid again Genome duplication probably gave biodiversity a decisive evolutionary boost. A Chinese-German research team led by Axel Meyer from the University of Konstanz has now investigated the early phases of the process known as re-diploidization. The results show that the fusion of chromosome sets is asynchronous.https://www.gesundheitsindustrie-bw.de/en/article/press-release/turning-four-two-how-duplicated-genomes-become-diploid-again
Press release - 28/04/2026 Breast cancer brain metastases: patterns in immune cells could improve therapy decisions Brain metastases are among the most serious complications of breast cancer. Researchers at Heidelberg University, DKFZ, and UKHD have concluded an investigation of the immune cells in the brain tissue surrounding these breast cancer brain metastases. Their findings: spatial distribution patterns of immune cells are associated with prolonged patient survival. These findings could help to guide use of immunotherapies for breast cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/breast-cancer-brain-metastases-patterns-immune-cells-could-improve-therapy-decisions
Press release - 18/04/2024 Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. https://www.gesundheitsindustrie-bw.de/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform
Press release - 14/03/2025 Tool identifies specific viruses to combat dangerous bacteria University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibioticshttps://www.gesundheitsindustrie-bw.de/en/article/press-release/tool-identifies-specific-viruses-combat-dangerous-bacteria
Press release - 01/03/2024 Using Data to Improve Understanding of Relationships between Proteins and Diseases Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases